SaaS entity
Every one of those 1 sits in a single category, earnings. Of the tracked stories, 1 of 1 also mention Bayer Aktiengesellschaft, the most common co-covered peer. They are better corroborated than the beat average, carrying 28 original sources each against 5.6 for the same window.
Last mentioned: Feb 20, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, earnings. Of the tracked stories, 1 of 1 also mention Bayer Aktiengesellschaft, the most common co-covered peer. They are better corroborated than the beat average, carrying 28 original sources each against 5.6 for the same window. Their average consequence score of 7 runs below the beat's 7.9 for that window. Genmab A/S appears in 1 tracked SaaS story from February 18, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 35 SaaS stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Genmab A/S. Shared-story counts are live from our verified record — not editorial picks.
A wave of Q4 earnings reports reveals a tightening fiscal environment for major players like Genmab and Santos, even as specialized biotech firms see massive gains from clinical breakthroughs. Market reactions remain erratic, with several companies experiencing share price declines despite meeting or exceeding operational targets.
Genmab A/S is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
